TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05671757

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will receive 4 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will receive 4-8 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will receive 4-16 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
Study: NCT06492408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab
Description: This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks, total 3-4 times.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks, total 3-4 times.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks, total 3-4 times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab
Description: This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks, total 3-4 times.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks, total 3-4 times.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks, total 3-4 times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab
Description: This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks, total 3-4 times.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks, total 3-4 times.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks, total 3-4 times.
Study: NCT06409858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: Twice-weekly mat Pilates class for 8 weeks, either in person or online (depending on participant availability)
Study: NCT05061992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: Participants will take 20 grams (dissolved in 4ounces of water/beverage) doses of lactulose twice daily (upon awakening and then 4 hours later) for 28 days.~In addition, outcome measurements will be completed at baseline and day 28.
Study: NCT05568758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic lymphatic pump technique
Description: The subject lies in the supine position; the therapist stands at the patient's head, facing the subject. The therapist then, places the thenar eminence of each hand to the pectoral region inferior to the clavicle and the other fingers are spread around the thoracic cage and angled toward the body's side to create a consistent, compressive force across the thoracic cage. The subject is then asked to breathe in deeply and breathe out. While breathing out, rhythmic oscillatory compression in the posterior and caudal direction is applied to the chest wall. By the end of the expiratory phase, the compressive force is maintained, and the subject is asked to take another deep breath. In this way, the subject encountered some resistance equivalent to the chest-wall movement during inspiration. The maneuver is repeated for five respiratory cycles, after that the therapist slowly reduces the compressive force and withdraws his hands.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises (stretching and strenghtening )
Description: stretching exercises include: Hamstring stretching exercises~Lower back stretching exercises :~strenghtening exercises include:~Abdominal curl up exercises :~Supine bridging exercises. Trunk extension exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises (stretching and strenghtening )
Description: stretching exercises include: Hamstring stretching exercises~Lower back stretching exercises :~strenghtening exercises include:~Abdominal curl up exercises :~Supine bridging exercises. Trunk extension exercises
Study: NCT06432140

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VGN-R09b injection
Description: Two levels of VGN-R09b will be injected into bilateral putamen in dose-escalating phase, and one dose level will be injected in dose confirming phase
Study: NCT05694260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bempedoic acid
Description: Once daily oral dosing with oral tablets or oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bempedoic acid
Description: Once daily oral dosing with oral tablets or oral suspension.
Study: NCT05229510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg/mL Virazole Inhalant Product
Description: 50 mg/mL Virazole (10 or 20 ml total volume) aerosolized and administered until solution depleted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg/mL Virazole Inhalant Product
Description: 50 mg/mL Virazole (10 or 20 ml total volume) aerosolized and administered until solution depleted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg/mL Virazole Inhalant Product
Description: 100 mg/mL Virazole (10 or 20 ml total volume) aerosolized and administered until solution depleted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg/mL Virazole Inhalant Product
Description: 100 mg/mL Virazole (10 or 20 ml total volume) aerosolized and administered until solution depleted
Study: NCT05694260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bempedoic acid
Description: Once daily oral dosing with oral tablets or oral suspension.
Study: NCT06180694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminiscence therapy
Description: In the research, reminiscence therapies will be carried out once a week for 8 weeks, in sessions of approximately 45 minutes.
Study: NCT05822544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC-6740 Oral Solution
Description: Oral solution of TLC-6740

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-to-match
Study: NCT05822544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC-6740 Tablet
Description: Tablet formulation of TLC-6740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Metabolizing Enzyme
Description: Oral dose of omeprazole, voriconazole, or itraconazole
Study: NCT05265052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3D1002 (50 mg)(Phase IIa)
Description: 1 tablet of 3D1002 per oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3D1002 (100 mg)(Phase IIa)
Description: 2 tablets of 3D1002 per oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3D1002 (150 mg)(Phase IIa)
Description: 3 tablets of 3D1002 per oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3D1002 monotherapy (Phase IIb)
Description: 3D1002 is administered at recommended dose with mimic OxyContin tablets.
Study: NCT06230679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive Neuromodulation
Description: Patients receive non-invasive neurostimulation through the Nesa device

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Non-invasive Neuromodulation
Description: The same protocol described for the experimental group will be applied, but electrical stimulation device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
Study: NCT05265052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OxyContin monotherapy (Phase IIb)
Description: OxyContin is administered at an initial dose of 10 mg per dose with mimic 3D1002 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3D1002 + OxyContin (Phase IIb)
Description: 3D1002 is administered at recommended dose, and OxyContin is administered at an initial dose of 10 mg per dose.
Study: NCT05965986

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: PREPS only
Description: Participants will be guided through an education program and exercise program that will cover topics. Participants will have flexibility as to when and how often then need to review material. Participants will be directed to completed on-screen interactive quizzes to re-enforce learning. Participants are encouraged to pose any questions regarding the material they are learning within the education modules to the research team for further clarification.~The intervention group will be asked to participate in the program (6 weeks), but after their surgery, they will not be asked to continue the education or exercise program. However, they will be tracking their activity and adherence to physical therapy through a log for one year post-operative.
Study: NCT06166004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: Balance Training device with VR

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Person-Specific Rehabilitation Program
Description: Person-Specific Rehabilitation Program
Study: NCT06640868

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MyChart nurse message
Description: Receipt of a MyChart nurse message around 34 weeks encouraging RSV vaccination

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MyChart nurse message
Description: Receipt of a MyChart nurse message around 34 weeks encouraging RSV vaccination

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMFM video
Description: Receipt of SMFM video around 34 weeks encouraging RSV vaccination

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMFM video
Description: Receipt of SMFM video around 34 weeks encouraging RSV vaccination

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visual aid
Description: Receipt of a visual aide encouraging RSV vaccination at 28-30 wks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visual aid
Description: Receipt of a visual aide encouraging RSV vaccination at 28-30 wks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visual aid
Description: Receipt of a visual aide encouraging RSV vaccination at 28-30 wks
Study: NCT06481813

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Sampling (2*8mL Tubes)
Description: Patients will be sampled from 2 x 8 mL blood tubes (EDTA tubes)

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Sampling (2*8mL Tubes)
Description: Patients will be sampled from 2 x 8 mL blood tubes (EDTA tubes)

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Sampling (2*8mL Tubes)
Description: Patients will be sampled from 2 x 8 mL blood tubes (EDTA tubes)

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Sampling (2*8mL Tubes)
Description: Patients will be sampled from 2 x 8 mL blood tubes (EDTA tubes)

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Sampling (2*8mL Tubes)
Description: Patients will be sampled from 2 x 8 mL blood tubes (EDTA tubes)

Intervention type: OTHER
Group type: OTHER
Intervention: PBMC Sampling (1*8mL Tubes)
Description: Patients will be sampled from 1 x 8 mL PBMC

Intervention type: OTHER
Group type: OTHER
Intervention: PBMC Sampling (1*8mL Tubes)
Description: Patients will be sampled from 1 x 8 mL PBMC

Intervention type: OTHER
Group type: OTHER
Intervention: PBMC Sampling (1*8mL Tubes)
Description: Patients will be sampled from 1 x 8 mL PBMC

Intervention type: OTHER
Group type: OTHER
Intervention: Paxgene Sampling
Description: Patients will be sampled from 1 x 8 mL of blood with Paxgene Tube

Intervention type: OTHER
Group type: OTHER
Intervention: Paxgene Sampling
Description: Patients will be sampled from 1 x 8 mL of blood with Paxgene Tube

Intervention type: OTHER
Group type: OTHER
Intervention: Paxgene Sampling
Description: Patients will be sampled from 1 x 8 mL of blood with Paxgene Tube

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Extended biopsies of tumor lesions
Description: Regarding the ancillary study, as part of the care, patients are biopsied at diagnosis and during relapse(s). For metastatic patients with multiple sites, one site (the most accessible) is chosen and biopsied in interventional radiology or pulmonology.~The material used is: 17-18G biopsy needle / Sampling chamber volume of 0.01 cm³ to 0.02 cm³.~For a standard biopsy as part of the care, 3 samples are taken (total volume of 0.03 cm³ to 0.06 cm³). Inclusion in the ancillary study would add one sample using the same biopsy path, resulting in an additional volume of 0.01 cm³ to 0.02 cm³.~In the case of a complex biopsy, no additional sampling related to the research will be performed.
Study: NCT06151717

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT06066099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP31969
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP31969
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets
Study: NCT05731544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMF-219
Description: Investigational Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMF-219
Description: Investigational Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMF-219
Description: Investigational Product
Study: NCT05965986

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: PREPS and therapy
Description: Participants will be guided through an education program and exercise program that will cover topics. Participants will have flexibility as to when and how often then need to review material. Participants will be directed to completed on-screen interactive quizzes to re-enforce learning. Participants are encouraged to pose any questions regarding the material they are learning within the education modules to the research team for further clarification.~The intervention group will be asked to participate in the program (6 weeks), but after their surgery, they will not be asked to continue the education or exercise program. However, they will be tracking their activity and adherence to physical therapy through a log for one year post-operative. In addition, participants will have a therapist call on week 2 and 4 of the program and then one week after surgery to check in and ensure the patient is meeting all milestones and answer any questions.
Study: NCT05229510

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (10 or 20 ml total volume) aerosolized and administered until solution depleted
Study: NCT05731544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMF-219
Description: Investigational Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMF-219
Description: Investigational Product
Study: NCT06407427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App for in-bed conditioning exercises
Description: Participants will use an application (app) in facilitating in-bed conditioning exercises for hospitalized patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: All participants will receive usual care in the post-operative setting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: All participants will receive usual care in the post-operative setting.
Study: NCT06115603

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabigerol
Description: 1 mL of 80mg Cannabigerol once during experimental session

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mL of placebo once during experimental session
Study: NCT06166004

Intervention type: OTHER
Group type: OTHER
Intervention: Person-Specific Rehabilitation Program
Description: Person-Specific Rehabilitation Program
Study: NCT06273540

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: STP7 (mavoglurant) or Placebo
Description: STP7 (mavoglurant) or Placebo twice a day (BID) from Days 3 to 9 according to the following dosing schedule: Day 3: 50 mg BID; Day 4: 100 mg BID; Days 5-9: 200 mg BID, and will take only the morning dose of STP7 (200 mg) on Day 10.~Cocaine / Saline~Participants will undergo cocaine/saline i.v. challenge sessions according to the schedule and doses:~* Screening (Session 1, Day -2): 20 mg cocaine, followed by a saline infusion, followed by 40 mg cocaine~* Baseline (Session 2, Day 1): saline or 20 mg cocaine followed by either 20 mg cocaine or saline.~* Baseline (Session 3, Day 2): saline or 40 mg cocaine followed by either 40 mg cocaine or saline.~* Treatment (Session 4, Day 9): saline or 20 mg cocaine followed by either 20 mg cocaine or saline.~* Treatment (Session 5, Day 10): saline or 40 mg cocaine followed by either 40 mg cocaine or saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP7 (mavoglurant) or Placebo
Description: STP7 (mavoglurant) or Placebo twice a day (BID) from Days 3 to 9 according to the following dosing schedule: Day 3: 50 mg BID; Day 4: 100 mg BID; Days 5-9: 200 mg BID, and will take only the morning dose of STP7 (200 mg) on Day 10.~Cocaine / Saline~Participants will undergo cocaine/saline i.v. challenge sessions according to the schedule and doses:~* Screening (Session 1, Day -2): 20 mg cocaine, followed by a saline infusion, followed by 40 mg cocaine~* Baseline (Session 2, Day 1): saline or 20 mg cocaine followed by either 20 mg cocaine or saline.~* Baseline (Session 3, Day 2): saline or 40 mg cocaine followed by either 40 mg cocaine or saline.~* Treatment (Session 4, Day 9): saline or 20 mg cocaine followed by either 20 mg cocaine or saline.~* Treatment (Session 5, Day 10): saline or 40 mg cocaine followed by either 40 mg cocaine or saline.
Study: NCT05530538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BrainWeighve App
Description: 46 total adolescents (14-18 years old) with %BMIp95 will be recruited via various sources (e.g., clinic referrals, flyers, social media advertising) to participate in one of two stages of the study: the beta testing stage or the trial stage. Beta testing will enroll two successive groups of eight teens to test the app for three weeks; participants will be assessed in-person pre- and post-intervention. After each group, the app will be modified to incorporate their feedback in order to promote youth engagement. The trial stage will enroll 30 adolescents to participate in a four-month intervention; participants will complete three assessments, baseline, post-intervention (both in-person) and one-month post-intervention (either in-person or virtually).
Study: NCT05081271

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Homologous booster
Description: Group 1 will receive a booster dose of a homologous vaccine and Group 2 a heterologous vaccine. This means Ad26.COV2.S if they originally received BNT162b2 or mRNA-1273 or vice versa

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Heterologous booster
Description: Group 1 will receive a booster dose of a homologous vaccine and Group 2 a heterologous vaccine. This means Ad26.COV2.S if they originally received BNT162b2 or mRNA-1273 or vice versa
Study: NCT05420337

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group ıntramuscular
Description: Group I will be applied 20 ml of % 0.25 bupivacain internal oblique and transversus abdominis muscle and 0.1 mg/kg morphine ıntramuscular. The blocks will be administered under general anesthesia in supine position by the same anesthesiologist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group TAP
Description: Group T will be applied 20 ml of % 0.25 bupivacain and 0.1 mg/kg morphine internal oblique and transversus abdominis muscle. The blocks will be administered under general anesthesia in supine position by the same anesthesiologist.
Study: NCT06029218

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proteus ONE one daily beam
Description: A single daily beam is used, doubling the dose delivered for this treatment incidence.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Proteus ONE two daily beam
Description: two daily beams are used, in accordance with the initial treatment plan and the patient's standard of care
Study: NCT05894759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological stress relief techniques
Description: Psychological stress relief techniques

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Psychological stress relief techniques
Description: Psychological stress relief techniques
Study: NCT05852990

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Glutamine plus L. reuteri
Description: Glutamine plus Lactobacillus reueri twice daily for up to 6 weeks or death
Study: NCT05838612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat acclimation
Description: Participants will complete a 7-day passive heat acclimation protocol consisting of immersion in warm water (\~40°C) for 1 hour over 7 consecutive days.